Yes, Milestone Pharmaceuticals has successfully executed several public stock offerings since transitioning into a publicly traded corporation on the NASDAQ exchange. These public offerings, including follow-on equity raises and at-the-market facilities managed through major investment banking partners, were designed to secure the vital capital necessary to fund extensive clinical trials, regulatory submissions, and commercial product launches. While public offerings provide essential funding for early-stage biopharmaceutical firms to sustain operations without excessive debt burdens, they also result in equity dilution for existing shareholders, which remains an important factor monitored closely by market participants.